GlassScriptPhysician profile
Denise Evette Claridy
NPI 1386102119
$6,606.79
in general payments reported to CMS, 2019-2025
26 companies · $3,618 in 2025
The $3,618 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $360 · 2023: $567 · 2024: $2,061 · 2025: $3,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,128 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,128.21 |
| Education | $118.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,481.24 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,350.38 | 2024-2025 | |
| Glaxosmithkline, LLC. | $868.00 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $722.88 | 2022-2025 | Dupixent |
| Csl Behring | $458.63 | 2024-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $303.51 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $229.19 | 2023-2025 | Takhzyro, Hyqvia |
| Biocryst US Sales Co., LLC | $199.99 | 2025 | Orladeyo |
| Amgen INC. | $167.31 | 2024-2025 | Tezspire |
| Verona Pharma, INC. | $159.68 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $140.88 | 2024-2025 | Xembify |
| Genentech USA, INC. | $83.80 | 2023-2025 | Xolair |
| Organon LLC | $66.08 | 2025 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| Kaleo, INC. | $46.66 | 2022-2023 | Auvi-Q |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42.70 | 2024-2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $33.52 | 2023 | |
| Pharming Healthcare, INC. | $29.57 | 2025 | Ruconest |
| Leo Pharma INC. | $27.47 | 2025 | Anzupgo |
| Phadia US INC. | $24.97 | 2024 | Immunocap |
| Paratek Pharmaceuticals, INC. | $23.99 | 2025 | Xhance |
| Incyte Corporation | $23.79 | 2025 | Opzelura |
| Mylan Specialty L.P. | $23.36 | 2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $16.30 | 2024 | Xarelto |
| Abbvie INC. | $12.86 | 2023 | |
| Hikma Pharmaceuticals USA | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Claridy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.